January 3, 2019
Sugar.IQ — the digital diabetes assistant for Guardian Connect system users that is jointly supported by Medtronic and IBM Watson — has a new feature that uses artificial intelligence to predict future low glucose events.
Called IQcast, the feature tells users whether they have a low, medium or high chance of dropping below the target blood glucose range within the next one to four hours. These...
November 21, 2018
Ascensia Diabetes Care’s Contour Diabetes app — a mobile tool to monitor trends in blood glucose levels that connects to the Contour Next One glucometer — has received yet another update. As of Monday, iPhone users can transfer blood glucose and carbohydrate data from their app to records kept within the Apple Health platform.
After opting in, data collected through Ascensia’s app will...
November 6, 2018
Apple’s healthcare patent update. A new Hong Kong and European trademark updates the classification of Apple’s AirPods to include health, fitness, exercise and wellness sensors (kudos to Patently Apple, which spotted the update). The updated classification also includes language concerning the transmission of biometric data, heart rate, body movement and burned calories.
Despite this and other...
September 5, 2018
This morning digital diabetes coaching platform Fit4D landed another $4 million in funding. The round was led by SJF Ventures, C&B Capital, Esther Dyson, and North Haven Capital, with participation from Blue Cross and Blue Shield of Nebraska and StarUP Health.
The New York City-based startup plans to use the money to continue clinical validation and development of its product.
May 11, 2018
Hello Heart — maker of an app-driven platform designed to help employees manage hypertension, heart rate, and cardiovascular health — has announced the release of a new service for diabetes management.
Both the cardiovascular and diabetes services are housed within the larger Hello Heart app, explained CEO Maayan Cohen, a move that represent the company’s shifting approach from a single-disease...
February 20, 2018
Roche’s Accu-Chek Connect Diabetes Management App has hit yet another snag with the FDA. On February 15, the agency issued a Class 2 Device Recall for certain software versions of the app due to a bug that could lead users to self-administer inappropriate doses of insulin.
Roche issued an update correcting the bug back in June, and has posted notices on the Accu-Chek website urging users to...
November 29, 2017
A slew of digital diabetes care companies have announced integrations with the upcoming virtual Type 2 diabetes management platform being developed by Onduo, a joint venture of Verily and Sanofi. These announced services include Voluntis’ Insulia, a digital insulin dose recommendation and coaching system; Glytec’s Glucommander Outpatient, cloud-based software that evaluates blood glucose and...
May 5, 2017
Germantown, Maryland-based Senseonics may not be rolling in profits, but the company – which is working towards commercializing its implantable, long-term continuous glucose monitor – isn’t holding back on characterizing their position as strong.
With expanded commercial launches in Germany and Sweden, plans for a presence in eight European countries by mid-2017, a CE Mark for their second...
March 8, 2017
San Francisco-based startup Virta Health officially launched today with a mission to reverse type 2 diabetes. Formed by a team of doctors, scientists and technologists hailing from Stanford, MIT and Harvard – and backed by $37 million from some big name investors – Virta is approaching type 2 diabetes with a goal to use personalized nutrition, one-on-one coaching and remote monitoring to reverse...
February 16, 2017
Vienna and San Diego-based digital health company mySugr has come out of the International Conference on Advanced Technologies and Treatments for Diabetes with two big pieces of news: study results that show impressive efficacy of the app in high-risk populations and an expansion of its partnership with Roche.
The study looked at 440 mySugr users randomly selected from a group of high-risk (HbA1C...